Effects of galactosemia in utero
| Autor: | J. B. Holton |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Galactosemias
Male Fetus medicine.medical_specialty Amniotic fluid business.industry Birth weight Galactitol Galactosemia Galactose medicine.disease chemistry.chemical_compound Fetal Diseases Endocrinology chemistry In utero Internal medicine Pediatrics Perinatology and Child Health Medicine Gestation Humans Female Abnormality business |
| Zdroj: | European journal of pediatrics. 154(7 Suppl 2) |
| ISSN: | 0340-6199 |
| Popis: | There is direct evidence that in galactosemia, due to galactose-1-phosphate uridyltransferase deficiency, galactose, galactose-1-phosphate and galactitol accumulate in the fetus by week 20 of gestation. The metabolic abnormality may develop earlier than this, however, since the key enzymes in galactose metabolism have been shown to be present in normal fetal liver from the 10th week of gestation. There has been a single report of increased galactitol in amniotic fluid obtained at 10 weeks gestation, the outcome being a baby affected with galactosemia. Cataract formation in the fetus is rare and the only direct evidence that galactosemia may have harmful effects in utero. However, it has been concluded that the liver pathology seen in some patients who died in the neonatal period originated prenatally, and some studies have found that galactosemia is associated with reduced birth weight. Reports of two patients with histologically normal ovaries very soon after birth have been cited as evidence against gonadal dysfunction arising during fetal life, but it should be noted that this is not a constant feature in female galactosemics. Other observations, particularly those made from animal models, would suggest that ovarian dysfunction is most likely to have been caused in utero. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink